IOL Chemicals and Pharmaceuticals · NSE: IOLCP · BSE: 524164
Q4 FY25 results · Jan–Mar 2025
IOL Chemicals and Pharmaceuticals reported revenue from operations of ₹527.78 crore (up 4.7% from Q4 FY24) and net profit of ₹31.42 crore (up 13.8% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 527.78 | 503.92 | +4.7% | 523.30 | +0.9% |
| Other income | 4.53 | 7.52 | −39.8% | 4.07 | +11.3% |
| Total income | 532.31 | 511.44 | +4.1% | 527.37 | +0.9% |
| Profit before tax | 44.70 | 37.20 | +20.2% | 27.80 | +60.8% |
| Net profit for the period | 31.42 | 27.62 | +13.8% | 20.53 | +53.0% |
| EPS, basic (₹) | 1.07 | 4.71 | not comparable | 3.50 | not comparable |
| Net margin (%) | 6.0 | 5.5 | 3.9 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 527.78 | 503.92 | +4.7% | 523.30 | +0.9% |
| Other income | 4.52 | 7.52 | −39.9% | 4.07 | +11.1% |
| Total income | 532.30 | 511.44 | +4.1% | 527.37 | +0.9% |
| Profit before tax | 44.90 | 37.77 | +18.9% | 27.82 | +61.4% |
| Net profit for the period | 31.62 | 28.19 | +12.2% | 20.55 | +53.9% |
| EPS, basic (₹) | 1.08 | 4.80 | not comparable | 3.50 | not comparable |
| Net margin (%) | 6.0 | 5.6 | 3.9 |
Consolidated
- Filed with BSE
- 16 May 2025, 20:52 IST
- Board meeting
- 16 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 May 2025, 20:52 IST
- Board meeting
- 16 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE